Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway

Neuroscience Letters

Volumn 513, Issue 2, 2012, Pages 193-197

  Renner, Dan B ^a   Frey, William H ^a   Hanson, Leah R ^a  

^a REGIONS HOSPITAL   (United States)

Author keywords

Intranasal; Olfactory bulbs; Olfactory nerve pathway; SiRNA

Indexed keywords

SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BOWMAN MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE; GENE EXPRESSION; GENE SILENCING; IMAGE ANALYSIS; MALE; MITRAL CELL; MOUSE; NONHUMAN; NOSE CAVITY; OLFACTORY BULB; OLFACTORY EPITHELIUM; OLFACTORY NERVE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS;

ADMINISTRATION, INTRANASAL; ANIMALS; MALE; MICE; OLFACTORY BULB; OLFACTORY NERVE; OLFACTORY PATHWAYS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84859000580     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.02.037     Document Type: Article

References (34)

1. Benedict C., Frey W.H., Schioth H.B., Schultes B., Born J., Hallschmid M. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp. Gerontol. 2011, 46:112-115.
2. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J., Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004, 29:1326-1334.
3. Bortolozzi A., Castane A., Semakova J., Santana N., Alvarado G., Cortes R., Ferres-Coy A., Fernandez G., Carmona M.C., Toth M., Perales J.C., Montefeltro A., Artigas F. Selective siRNA-mediated suppression of 5-HT(1A) autoreceptors evokes strong anti-depressant-like effects. Mol. Psychiatry 2011, (Epub ahead of print).
4. Chen X.Q., Fawcett J.R., Rahman Y.E., Ala T.A., Frey I.W. Delivery of nerve growth factor to the brain via the olfactory pathway. J. Alzheimers Dis. 1998, 1:35-44.
5. W.H.F.I. Christoph Reinjard, Delivery of Polynucleotide Agents to the Central Nervous System, US 2009/0264506 A1 (2009).
6. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., Green P.S., Leverenz J., Cross D., Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
7. Danielyan L., Schafer R., von Ameln-Mayerhofer A., Bernhard F., Verleysdonk S., Buadze M., Lourhmati A., Klopfer T., Schaumann F., Schmid B., Koehle C., Proksch B., Weissert R., Reichardt H.M., Van den Brandt J., Buniatian G.H., Schwab M., Gleiter C.H., Frey W.H. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res. 2011, 14:3-16.
8. Danielyan L., Schafer R., von Ameln-Mayerhofer A., Buadze M., Geisler J., Klopfer T., Burkhardt U., Proksch B., Verleysdonk S., Ayturan M., Buniatian G.H., Gleiter C.H., Frey W.H. Intranasal delivery of cells to the brain. Eur. J. Cell Biol. 2009, 88:315-324.
9. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J. Pharm. Sci. 2009, 98:2501-2515.
10. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99:1654-1673.
11. Dykxhoorn D.M., Lieberman J. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu. Rev. Biomed. Eng. 2006, 8:377-402.
12. Field P., Li Y., Raisman G. Ensheathment of the olfactory nerves in the adult rat. J. Neurocytol. 2003, 32:317-324.
13. Francis G.J., Martinez J.A., Liu W.Q., Xu K., Ayer A., Fine J., Tuor U.I., Glazner G., Hanson L.R., Frey W.H., Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008, 131:3311-3334.
14. W.H. Frey 2nd, Method of Administering Neurologic Agents to the Brain 5,624,898 (1997).
15. Hanson L.R., Frey W.H. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008, 9(Suppl. 3):S5.
16. Hanson L.R., Martinez P.M., Taheri S., Kamsheh L., Mignot E., Frey W.H.I. Intranasal administration of hypocretin 1 (Orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv. Technol. 2004, 4:81-86.
17. Hashizume R., Ozawa T., Gryaznov S.M., Bollen A.W., Lamborn K.R., Frey W.H., Deen D.F. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neurol. Oncol. 2008, 10:112-120.
18. Jansson B., Bjork E. Visualization of in vivo olfactory uptake and transfer using fluorescein dextran. J. Drug Target. 2002, 10:379-386.
19. Kim I., Kim S., Lee J. Gener knockdown in the olfactory bulb, amygdala, and hypothalamus by intranasal siRNA administration. Kor. J. Anat. 2009, 42:285-292.
20. Li Y., Field P.M., Raisman G. Olfactory ensheathing cells and olfactory nerve fibroblasts maintain continuous open channels for regrowth of olfactory nerve fibres. Glia 2005, 52:245-251.
21. Lingor P., Bahr M. Targeting neurological disease with RNAi. Mol. Biosyst. 2007, 3:773-780.
22. Ma Y.P., Ma M.M., Ge S., Guo R.B., Zhang H.J., Frey W.H., Xu G.L., Liu X.F. Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats. Brain Res. Bull. 2007, 74:271-277.
23. Nguyen T., Menocal E.M., Harborth J., Fruehauf J.H. RNAi therapeutics: an update on delivery. Curr. Opin. Mol. Ther. 2008, 10:158-167.
24. Nonaka N., Farr S.A., Kageyama H., Shioda S., Banks W.A. Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J. Pharmacol. Exp. Ther. 2008, 325:513-519.
25. Nores J.M., Biacabe B., Bonfils P. [Olfactory disorders in Alzheimer's disease and in Parkinson's disease. Review of the literature]. Ann. Med. Intern. (Paris) 2000, 151:97-106.
26. Reger M.A., Watson G.S., Frey W.H., Baker L.D., Cholerton B., Keeling M.L., Belongia D.A., Fishel M.A., Plymate S.R., Schellenberg G.D., Cherrier M.M., Craft S. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 2006, 27:451-458.
27. Reger M.A., Watson G.S., Green P.S., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Cherrier M.M., Schellenberg G.D., Frey W.H., Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J. Alzheimers Dis. 2008, 13:323-331.
28. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C., DeGroodt W., Mehta P., Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70:440-448.
29. Ross T.M., Martinez P.M., Renner J.C., Thorne R.G., Hanson L.R., Frey W.H. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J. Neuroimmunol. 2004, 151:66-77.
30. Schwartz E.I. Potential application of RNAi for understanding and therapy of neurodegenerative diseases. Front. Biosci. 2009, 14:297-320.
31. Shim M.S., Kwon Y.J. Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010, 277:4814-4827.
32. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127:481-496.
33. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. 2009, 8:129-138.
34. Wu H., Hu K., Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin. Drug Deliv. 2008, 5:1159-1168.